Tonix Pharmaceuticals Holding Corp. has appointed Joseph Hand as its new General Counsel and Executive Vice President of Operations, signaling a strategic move to bolster its leadership team ahead of a potential product launch. Hand brings extensive experience from high-profile corporate transactions, including pivotal roles in Celgene's $74 billion acquisition by Bristol Myers Squibb and the $13.4 billion divestiture of Otezla® to Amgen.
The appointment comes at a critical juncture for Tonix, which is preparing to submit a New Drug Application to the FDA this month for TNX-102 SL, a potential treatment for fibromyalgia. The drug candidate has completed two statistically significant phase 3 studies and has received Fast Track designation from the FDA, indicating its potential significance in addressing this challenging chronic pain condition.
Hand's expertise spans legal, human resources, and corporate services, suggesting he will play a crucial role in guiding Tonix through potential regulatory approvals and strategic corporate developments. His background in major pharmaceutical transactions positions the company to potentially navigate complex corporate strategies and partnerships.
Beyond the fibromyalgia treatment, Tonix is developing multiple innovative therapies, including antiviral agents for the Department of Defense and treatments for central nervous system disorders. The company's diverse portfolio and Hand's extensive experience could prove instrumental in advancing its research and commercial objectives.
